The immunostimulatory properties of TLR7/8 agonists, such as resiquimod, have been exploited for cancer immunotherapy. Here, the authors design platelet membrane-cloaked nanoparticles for selective intratumoral delivery of resiquimod, resulting in potent anti-tumor immune response in a range of preclinical solid tumors.
- Baharak Bahmani
- Hua Gong
- Jie Zhang
